Proton therapy reduced estimated immune-cell dose in postoperative esophageal radiotherapy
Estimated immune-cell dose predicted lymphocyte decline and was substantially lower with proton plans, particularly spot-scanning proton arc therapy.
Latest
Acuros XB increased synthetic CT dose differences but remained clinically acceptable
Acuros XB was more sensitive than AAA to synthetic CT discrepancies, but target-dose differences remained small in prostate and glioma plans.
Multimodal models appear most promising for predicting rectal cancer pathological complete response
No individual clinical, imaging, blood, or molecular marker reliably predicted pathological complete response, while integrated multimodal models showed greater potential.
Hybrid radiomics model improved tomotherapy PSQA prediction but transferred poorly across centres
Combining plan complexity with three-dimensional dose radiomics improved tomotherapy PSQA prediction, although performance deteriorated substantially during cross-institution testing.
Glioblastoma brachytherapy remains limited by non-standardized dosimetry
Modern intracavitary platforms can intensify pericavitary dose immediately after surgery, but standardized patient-specific dosimetry and comparative clinical evidence remain lacking.
Biopsy localization uncertainty substantially altered HDR prostate brachytherapy dose estimates
Millimeter-scale localization uncertainty shifted assigned biopsy doses by several Gy and made nominal DVH threshold classification frequently unreliable.
Bragg peak proton FLASH matched CyberKnife plans and cut beam delivery to seconds
In 10 recurrent glioblastoma replans, Bragg peak proton FLASH improved conformity and reduced estimated beam delivery from approximately 17 minutes to under two seconds.
PROTEUS improved composite MFS but not conventional imaging-defined MFS
Perioperative apalutamide improved pathological response and composite MFS, but not conventional imaging-defined MFS, raising concern about overtreatment in broadly defined high-risk disease.
Prolonged first-generation antiandrogens showed no survival benefit with prostate radiotherapy
Extending first-generation antiandrogen therapy beyond short-term use was not associated with better survival and may increase early ADT discontinuation.
Bone metastasis trials need treatment-intent endpoints beyond pain response
Pain should remain central for symptomatic disease, but prevention, function, local control and skeletal events require separate standardized endpoints.
Additional PMMA changed mammography multimeter calibration coefficients by up to 42%
Spectral hardening altered multimeter calibration by up to 11% for kerma, 37% for HVL and 42% for voltage.
Five-fraction partial breast re-irradiation showed low toxicity after repeat lumpectomy
Twenty-five selected patients had 96% crude local control and no grade 3 toxicity after 26 Gy in five fractions.
Pelvic radiotherapy was associated with modest excess secondary uterine cancer risk
Twenty-year secondary uterine cancer incidence increased after pelvic radiotherapy, but absolute excess risk remained below two percentage points.
Early neuropsychological care did not improve three-month quality of life in brain metastases
ATHENA did not improve FACT-Br scores at three months, although an exploratory nine-month analysis favoured neuropsychological integration.
Planning-CT radiomics improved pretreatment prediction of poor rectal cancer response
Adding CTV radiomics increased internal AUROC from 0.507 to 0.754 for predicting poor response to rectal chemoradiotherapy.